DISEASE INDICATIONS: Hereditary angioedema (HAE)

MANUFACTURER: Shire Pharmaceuticals

USAGE: Subcutaneous

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Takhzyro is the brand name for the medication with the active ingredient lanadelumab. It is a prescription drug used for the prevention of hereditary angioedema (HAE) attacks in patients aged 12 years and older.